130 related articles for article (PubMed ID: 6895157)
1. Mullerian inhibiting substance inhibits growth of a human ovarian cancer in nude mice.
Donahoe PK; Fuller AF; Scully RE; Guy SR; Budzik GP
Ann Surg; 1981 Oct; 194(4):472-80. PubMed ID: 6895157
[TBL] [Abstract][Full Text] [Related]
2. Müllerian inhibiting substance inhibition of a human endometrial carcinoma cell line xenografted in nude mice.
Fuller AF; Budzik GP; Krane IM; Donahoe PK
Gynecol Oncol; 1984 Jan; 17(1):124-32. PubMed ID: 6546372
[TBL] [Abstract][Full Text] [Related]
3. Highly purified müllerian inhibiting substance inhibits human ovarian cancer in vivo.
Stephen AE; Pearsall LA; Christian BP; Donahoe PK; Vacanti JP; MacLaughlin DT
Clin Cancer Res; 2002 Aug; 8(8):2640-6. PubMed ID: 12171896
[TBL] [Abstract][Full Text] [Related]
4. Mullerian inhibiting substance reduction of colony growth of human gynecologic cancers in a stem cell assay.
Fuller AF; Krane IM; Budzik GP; Donahoe PK
Gynecol Oncol; 1985 Oct; 22(2):135-48. PubMed ID: 3932140
[TBL] [Abstract][Full Text] [Related]
5. Recombinant human Mullerian inhibiting substance inhibits long-term growth of MIS type II receptor-directed transgenic mouse ovarian cancers in vivo.
Pieretti-Vanmarcke R; Donahoe PK; Szotek P; Manganaro T; Lorenzen MK; Lorenzen J; Connolly DC; Halpern EF; MacLaughlin DT
Clin Cancer Res; 2006 Mar; 12(5):1593-8. PubMed ID: 16533786
[TBL] [Abstract][Full Text] [Related]
6. Subrenal capsule assay to test the viability of parenterally delivered müllerian inhibiting substance.
Donahoe PK; Krane I; Bogdén AE; Kamagata S; Budzik GP
J Pediatr Surg; 1984 Dec; 19(6):863-9. PubMed ID: 6084056
[TBL] [Abstract][Full Text] [Related]
7. Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer.
Pieretti-Vanmarcke R; Donahoe PK; Pearsall LA; Dinulescu DM; Connolly DC; Halpern EF; Seiden MV; MacLaughlin DT
Proc Natl Acad Sci U S A; 2006 Nov; 103(46):17426-31. PubMed ID: 17088539
[TBL] [Abstract][Full Text] [Related]
8. Enhanced purification and production of Müllerian inhibiting substance for therapeutic applications.
Donahoe PK; Clarke T; Teixeira J; Maheswaran S; MacLaughlin DT
Mol Cell Endocrinol; 2003 Dec; 211(1-2):37-42. PubMed ID: 14656474
[TBL] [Abstract][Full Text] [Related]
9. Mullerian inhibiting substance inhibits colony growth of a human ovarian carcinoma cell line.
Fuller AF; Guy S; Budzik GP; Donahoe PK
J Clin Endocrinol Metab; 1982 May; 54(5):1051-5. PubMed ID: 6895900
[TBL] [Abstract][Full Text] [Related]
10. Antibody against avian müllerian inhibiting substance (MIS) recognizes MIS on rat müllerian duct and human tumor cells.
Wang JJ; Teng CS
Proc Natl Sci Counc Repub China B; 1989 Oct; 13(4):267-75. PubMed ID: 2484046
[TBL] [Abstract][Full Text] [Related]
11. Mullerian inhibiting substance inhibits ovarian cell growth through an Rb-independent mechanism.
Ha TU; Segev DL; Barbie D; Masiakos PT; Tran TT; Dombkowski D; Glander M; Clarke TR; Lorenzo HK; Donahoe PK; Maheswaran S
J Biol Chem; 2000 Nov; 275(47):37101-9. PubMed ID: 10958795
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxic effects of müllerian inhibiting substance (MIS)?
Janssens JP; Noto V; van Tendeloo G; Bonte J; de Loecker W
Anticancer Res; 1988; 8(4):781-4. PubMed ID: 3178166
[TBL] [Abstract][Full Text] [Related]
13. Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS.
Masiakos PT; MacLaughlin DT; Maheswaran S; Teixeira J; Fuller AF; Shah PC; Kehas DJ; Kenneally MK; Dombkowski DM; Ha TU; Preffer FI; Donahoe PK
Clin Cancer Res; 1999 Nov; 5(11):3488-99. PubMed ID: 10589763
[TBL] [Abstract][Full Text] [Related]
14. Müllerian-inhibiting substance: an update.
Donahoe PK; Budzik GP; Trelstad R; Mudgett-Hunter M; Fuller A; Hutson JM; Ikawa H; Hayashi A; MacLaughlin D
Recent Prog Horm Res; 1982; 38():279-330. PubMed ID: 6896925
[No Abstract] [Full Text] [Related]
15. Minimal antiproliferative effect of recombinant müllerian inhibiting substance on gynecological tumor cell lines and tumor explants.
Wallen JW; Cate RL; Kiefer DM; Riemen MW; Martinez D; Hoffman RM; Donahoe PK; Von Hoff DD; Pepinsky B; Oliff A
Cancer Res; 1989 Apr; 49(8):2005-11. PubMed ID: 2702642
[TBL] [Abstract][Full Text] [Related]
16. Müllerian inhibiting substance regulates its receptor/SMAD signaling and causes mesenchymal transition of the coelomic epithelial cells early in Müllerian duct regression.
Zhan Y; Fujino A; MacLaughlin DT; Manganaro TF; Szotek PP; Arango NA; Teixeira J; Donahoe PK
Development; 2006 Jun; 133(12):2359-69. PubMed ID: 16687449
[TBL] [Abstract][Full Text] [Related]
17. Tissue-engineered cells producing complex recombinant proteins inhibit ovarian cancer in vivo.
Stephen AE; Masiakos PT; Segev DL; Vacanti JP; Donahoe PK; MacLaughlin DT
Proc Natl Acad Sci U S A; 2001 Mar; 98(6):3214-9. PubMed ID: 11248058
[TBL] [Abstract][Full Text] [Related]
18. Recombinant human mullerian inhibiting substance inhibits human ocular melanoma cell lines in vitro and in vivo.
Parry RL; Chin TW; Epstein J; Hudson PL; Powell DM; Donahoe PK
Cancer Res; 1992 Mar; 52(5):1182-6. PubMed ID: 1531323
[TBL] [Abstract][Full Text] [Related]
19. Müllerian inhibiting substance signaling uses a bone morphogenetic protein (BMP)-like pathway mediated by ALK2 and induces SMAD6 expression.
Clarke TR; Hoshiya Y; Yi SE; Liu X; Lyons KM; Donahoe PK
Mol Endocrinol; 2001 Jun; 15(6):946-59. PubMed ID: 11376113
[TBL] [Abstract][Full Text] [Related]
20. Timing and irreversibility of Müllerian duct inhibition in the embryonic reproductive tract of the human male.
Taguchi O; Cunha GR; Lawrence WD; Robboy SJ
Dev Biol; 1984 Dec; 106(2):394-8. PubMed ID: 6548718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
